Last reviewed · How we verify
PBS and TIV 50%
At a glance
| Generic name | PBS and TIV 50% |
|---|---|
| Sponsor | BiondVax Pharmaceuticals ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly (PHASE2)
- 2013/2017 H7N9 Prime-Boost Interval (PHASE2)
- 2017 A/H7N9 IIV Revaccination (PHASE2)
- Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine (PHASE1)
- A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines
- Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone (PHASE1)
- Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |